Subscribe to our Newsletters !!
The safety and quality of produced medicines is ex
Automation of sample preparation has become the mo
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Can gene editing be used as a life-saving treatmen
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-look
Pfizer Inc and BioNTech SE have consented to provide Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday.
The companies said, assuming achievement of the vaccine in clinical studies, they are on track to look for regulatory review to get the vaccine as early as October.
The companies didn’t disclose the financial details of their arrangement.
